Table 5.
Relationships of the NKG2D haplotypes with EULAR responses at 12th and 24th week of anti-TNF therapy
| EULAR 12 Weeks | EULAR 24 Weeks | |||
|---|---|---|---|---|
| No Response (Number (%)) | Good/Moderate Response (Number (%)) | No Response (Number (%)) | Good/Moderate Response (Number (%)) | |
| CGA | 10 (3.6%) | 80 (28.6%) | 5 (1.8%) | 80 (28.6%) |
| CGC | 20 (7.1%) | 225 (80.4%) | 12 (4.3%) | 224 (80.0%) |
| GAC | 1 (0.4%) a | 92 (32.9%) a | 4 (1.4%) | 87 (31.1%) |
| GGC | 6 (2.1%) b | 143 (51.1%) b | 8 (2.9%) | 135 (48.2%) |
a: GAC vs. others, p-value = 0.001, OR = 0.08, 95%CI (0.00, 0.52); b: GGC vs. others, p-value = 0.008, OR = 0.28, 95%CI (0.09, 0.78); haplotypes were composed from the following order: rs1049174 (C/G)–rs2255336 (A/G)–rs1154831 (C/A); OR: odds ratio; 95%CI: 95% confidence interval; EULAR: European League Against Rheumatism response criteria; percentages calculated in regard to a total number of patients.